Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
The aim of this health technology assessment is to assess the clinical-effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C.
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of moderate to severe hepatitis C was appraised by NICE in 2004 (TA751) and an appraisal specifically for mild hepatitis C was carried out in 2006 (TA1062). Both appraisals were based on independent assessment reports conducted by SHTAC.3,4
Since NICE's clinical guidance was published, there have been extensions to the licences for peginterferon alfa-2a and -2b. This health technology assessment is a part-review of the current NICE guidance and will be restricted to the patient subgroups that are affected by the licence extensions for the peginterferons. This includes people who have been previously treated with peginterferon alfa and ribavirin in combination and who either did not respond or who responded but relapsed, people who meet the licensed criteria for receiving shortened courses of combination therapy and people with HCV/HIV co-infection
The HTA Programme commissioned this technology assessment report on behalf of the National Institute for Health and Clinical Excellence.
i-210
Hartwell, D.
8ee30d05-c758-4d82-9e40-f977cd45bd58
Jones, J.
270b303b-6bad-4be7-8ea0-63d0e8015c91
Baxter, L.
eeafbfe7-ae7e-421f-a6b6-c6d9df80b6ef
Shepherd, J.
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
April 2011
Hartwell, D.
8ee30d05-c758-4d82-9e40-f977cd45bd58
Jones, J.
270b303b-6bad-4be7-8ea0-63d0e8015c91
Baxter, L.
eeafbfe7-ae7e-421f-a6b6-c6d9df80b6ef
Shepherd, J.
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Hartwell, D., Jones, J., Baxter, L. and Shepherd, J.
(2011)
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Health Technology Assessment, 15 (17), .
(doi:10.3310/hta15170).
Abstract
The aim of this health technology assessment is to assess the clinical-effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C.
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of moderate to severe hepatitis C was appraised by NICE in 2004 (TA751) and an appraisal specifically for mild hepatitis C was carried out in 2006 (TA1062). Both appraisals were based on independent assessment reports conducted by SHTAC.3,4
Since NICE's clinical guidance was published, there have been extensions to the licences for peginterferon alfa-2a and -2b. This health technology assessment is a part-review of the current NICE guidance and will be restricted to the patient subgroups that are affected by the licence extensions for the peginterferons. This includes people who have been previously treated with peginterferon alfa and ribavirin in combination and who either did not respond or who responded but relapsed, people who meet the licensed criteria for receiving shortened courses of combination therapy and people with HCV/HIV co-infection
The HTA Programme commissioned this technology assessment report on behalf of the National Institute for Health and Clinical Excellence.
Text
__userfiles.soton.ac.uk_Users_nsc_mydesktop_155443jones.pdf
- Version of Record
Restricted to Repository staff only
Request a copy
More information
Published date: April 2011
Organisations:
Other
Identifiers
Local EPrints ID: 155443
URI: http://eprints.soton.ac.uk/id/eprint/155443
ISSN: 1366-5278
PURE UUID: edd522c3-a64c-44ac-9827-197ee91969b3
Catalogue record
Date deposited: 28 May 2010 13:20
Last modified: 14 Mar 2024 02:38
Export record
Altmetrics
Contributors
Author:
D. Hartwell
Author:
L. Baxter
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
